U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07237568) titled 'A Study to Evaluate Efficacy and Safety of LNK01001 in Adults With Ankylosing Spondylitis' on Nov. 16.
Brief Summary: The aim of this study is to evaluate the efficacy and safety of LNK01001 in subjects with active ankylosing spondylitis.
The study is comprised of a 16-week randomized, double-blind, parallel-group, placebo-controlled period (the Double-Blind Period); a 36-week open-label, long-term extension period (the Open-Label Extension Period). In the Double-Blind Period, participants will be randomized in a 1:1 ratio to receive either LNK01001 or placebo twice daily (BID). Participants in the placebo group will be switched to...